Cargando…

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma

Uveal melanoma is the most common intraocular cancer in adults. Metastatic uveal melanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of T cell–directed therapy. Tebentafusp-tebn has been shown in a r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hua, Gwen, Carlson, Daniel, Starr, Jacqueline R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press LLC 2022
Materias:	Prescriber's Corner
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514125/ https://www.ncbi.nlm.nih.gov/pubmed/36199496 http://dx.doi.org/10.6004/jadpro.2022.13.7.8

Ejemplares similares

Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
por: Thompson, Daniel L., et al.
Publicado: (2020)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
por: Damato, Bertil E., et al.
Publicado: (2019)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer
por: Desai, Alisha, et al.
Publicado: (2022)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
por: Howlett, Sarah, et al.
Publicado: (2023)

Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
por: Montazeri, Kamaneh, et al.
Publicado: (2023)

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond
por: Gerard, C., et al.
Publicado: (2023)

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
por: Carvajal, Richard D., et al.
Publicado: (2022)

Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
por: Reiter, Selina, et al.
Publicado: (2023)

Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma
por: Carvajal, Richard D., et al.
Publicado: (2022)

Tebentafusp in first-line melanoma trials: An outperforming outlier
por: Olivier, Timothée, et al.
Publicado: (2022)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
por: Hamid, Omid, et al.
Publicado: (2023)

Safety around medicines for eye care
por: Khatun, Alaya, et al.
Publicado: (2021)

Improving adherence with eye medication: a patient-centred approach to prescribing
por: Wiafe, Boateng, et al.
Publicado: (2023)

Novel treatment paradigms for metastatic uveal melanoma
por: Patel, Sapna P., et al.
Publicado: (2022)

Identification of novel chemotherapeutic strategies for metastatic uveal melanoma
por: Fagone, Paolo, et al.
Publicado: (2017)

Darovasertib, a novel treatment for metastatic uveal melanoma
por: Cao, Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sqt4hb8k9095jfhssfm84ttl8v